

Chester A Mathis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2303878/publications.pdf>

Version: 2024-02-01

254
papers

36,940
citations

3933

88
h-index

3106

187
g-index

268
all docs

268
docs citations

268
times ranked

22434
citing authors

#	ARTICLE	IF	CITATIONS
1	Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. <i>Annals of Neurology</i> , 2004, 55, 306-319.	5.3	3,777
2	Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory. <i>Journal of Neuroscience</i> , 2005, 25, 7709-7717.	3.6	1,839
3	Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A β ₄₂ in humans. <i>Annals of Neurology</i> , 2006, 59, 512-519.	5.3	1,190
4	Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly. <i>Archives of Neurology</i> , 2008, 65, 1509.	4.5	923
5	Synthesis and Evaluation of ¹¹ C-Labeled 6-Substituted 2-Arylbenzothiazoles as Amyloid Imaging Agents. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 2740-2754.	6.4	921
6	Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. <i>Brain</i> , 2008, 131, 1630-1645.	7.6	837
7	¹¹ C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnesic mild cognitive impairment. <i>Brain</i> , 2008, 131, 665-680.	7.6	819
8	A β -amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. <i>Brain</i> , 2007, 130, 2837-2844.	7.6	739
9	Longitudinal assessment of A β and cognition in aging and Alzheimer disease. <i>Annals of Neurology</i> , 2011, 69, 181-192.	5.3	730
10	Fibrillar amyloid- β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 6820-6825.	7.1	700
11	¹¹ C-PiB PET assessment of change in fibrillar amyloid- β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. <i>Lancet Neurology</i> , 2010, 9, 363-372.	10.2	674
12	Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. <i>Biological Psychiatry</i> , 2001, 49, 81-96.	1.3	650
13	Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, 1528-1547.	4.3	622
14	The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. <i>Alzheimer's and Dementia</i> , 2015, 11, 1.	0.8	603
15	Pet imaging of serotonin 1A receptor binding in depression. <i>Biological Psychiatry</i> , 1999, 46, 1375-1387.	1.3	598
16	Episodic memory loss is related to hippocampal-mediated A β -amyloid deposition in elderly subjects. <i>Brain</i> , 2009, 132, 1310-1323.	7.6	596
17	Validating novel tau positron emission tomography tracer [¹⁸ F]AV-451 (T807) on postmortem brain tissue. <i>Annals of Neurology</i> , 2015, 78, 787-800.	5.3	535
18	Cortical Cholinergic Function Is More Severely Affected in Parkinsonian Dementia Than in Alzheimer Disease. <i>Archives of Neurology</i> , 2003, 60, 1745.	4.5	506

#	ARTICLE	IF	CITATIONS
19	Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. <i>Annals of Neurology</i> , 2007, 62, 229-234.	5.3	465
20	The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. <i>Alzheimer's and Dementia</i> , 2010, 6, 221-229.	0.8	464
21	Regional Cerebral Metabolic Alterations in Dementia of the Alzheimer Type. <i>Journal of Computer Assisted Tomography</i> , 1983, 7, 590-598.	0.9	434
22	Serotonin in Aging, Late-Life Depression, and Alzheimer's Disease: The Emerging Role of Functional Imaging. <i>Neuropsychopharmacology</i> , 1998, 18, 407-430.	5.4	432
23	Dynamics of the Microglial/Amyloid Interaction Indicate a Role in Plaque Maintenance. <i>Journal of Neuroscience</i> , 2008, 28, 4283-4292.	3.6	414
24	Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. <i>Life Sciences</i> , 2001, 69, 1471-1484.	4.3	408
25	Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1959-72.	5.0	398
26	Imaging A β Plaques in Living Transgenic Mice with Multiphoton Microscopy and Methoxy-XO4, a Systemically Administered Congo Red Derivative. <i>Journal of Neuropathology and Experimental Neurology</i> , 2002, 61, 797-805.	1.7	366
27	Amyloid- β Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods. <i>Journal of Nuclear Medicine</i> , 2013, 54, 70-77.	5.0	364
28	Amyloid Deposition Begins in the Striatum of Presenilin-1 Mutation Carriers from Two Unrelated Pedigrees. <i>Journal of Neuroscience</i> , 2007, 27, 6174-6184.	3.6	358
29	Binding of the Positron Emission Tomography Tracer Pittsburgh Compound-B Reflects the Amount of Amyloid- β in Alzheimer's Disease Brain But Not in Transgenic Mouse Brain. <i>Journal of Neuroscience</i> , 2005, 25, 10598-10606.	3.6	357
30	A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 295-298.	2.2	343
31	Serotonin-1A receptor imaging in recurrent depression: replication and literature review. <i>Nuclear Medicine and Biology</i> , 2007, 34, 865-877.	0.6	341
32	Molecular Imaging With Pittsburgh Compound B Confirmed at Autopsy. <i>Archives of Neurology</i> , 2007, 64, 431.	4.5	326
33	Increased Dopamine D2/D3 Receptor Binding After Recovery from Anorexia Nervosa Measured by Positron Emission Tomography and [11C]Raclopride. <i>Biological Psychiatry</i> , 2005, 58, 908-912.	1.3	314
34	Amyloid imaging in mild cognitive impairment subtypes. <i>Annals of Neurology</i> , 2009, 65, 557-568.	5.3	309
35	Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E4502-9.	7.1	309
36	Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. <i>Journal of Neurology</i> , 2006, 253, 242-247.	3.6	303

#	ARTICLE	IF	CITATIONS
37	The Binding of 2-(4-Methylaminophenyl)Benzothiazole to Postmortem Brain Homogenates Is Dominated by the Amyloid Component. <i>Journal of Neuroscience</i> , 2003, 23, 2086-2092.	3.6	269
38	Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid. <i>Biological Psychiatry</i> , 2009, 65, 927-934.	1.3	256
39	Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid- β ligand in transgenic mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 12462-12467.	7.1	253
40	Imaging of Amyloid Plaques and Neurofibrillary Tangles in the Aging Human Brain. <i>Current Pharmaceutical Design</i> , 2004, 10, 1469-1492.	1.9	237
41	Basal Cerebral Metabolism May Modulate the Cognitive Effects of $A\beta$ in Mild Cognitive Impairment: An Example of Brain Reserve. <i>Journal of Neuroscience</i> , 2009, 29, 14770-14778.	3.6	217
42	Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. <i>NeuroImage</i> , 2008, 39, 619-633.	4.2	201
43	The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015. <i>Alzheimer's and Dementia</i> , 2015, 11, 757-771.	0.8	199
44	Serotonin type-1A receptor imaging in depression. <i>Nuclear Medicine and Biology</i> , 2000, 27, 499-507.	0.6	182
45	Pathological correlations of [^{18}F]AV-451 imaging in non-Alzheimer tauopathies. <i>Annals of Neurology</i> , 2017, 81, 117-128.	5.3	174
46	Serotonin 1A Receptor Binding and Treatment Response in Late-Life Depression. <i>Neuropsychopharmacology</i> , 2004, 29, 2258-2265.	5.4	170
47	Diminished Glucose Transport in Alzheimer's Disease: Dynamic PET Studies. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1991, 11, 323-330.	4.3	167
48	Amyloid burden and neural function in people at risk for Alzheimer's Disease. <i>Neurobiology of Aging</i> , 2014, 35, 576-584.	3.1	166
49	SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1316-1322.	5.0	161
50	Anti- $A\beta$ antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. <i>Journal of Clinical Investigation</i> , 2005, 115, 428-433.	8.2	161
51	Altered 5-HT _{2A} Receptor Binding after Recovery from Bulimia-Type Anorexia Nervosa: Relationships to Harm Avoidance and Drive for Thinness. <i>Neuropsychopharmacology</i> , 2004, 29, 1143-1155.	5.4	158
52	Altered Brain Serotonin 5-HT _{1A} Receptor Binding After Recovery From Anorexia Nervosa Measured by Positron Emission Tomography and [^{11}C]WAY-100635. <i>Archives of General Psychiatry</i> , 2005, 62, 1032.	12.3	157
53	Pulse wave velocity is associated with $A\beta$ -amyloid deposition in the brains of very elderly adults. <i>Neurology</i> , 2013, 81, 1711-1718.	1.1	156
54	Development of Positron Emission Tomography $A\beta$ -Amyloid Plaque Imaging Agents. <i>Seminars in Nuclear Medicine</i> , 2012, 42, 423-432.	4.6	155

#	ARTICLE	IF	CITATIONS
55	Multisite study of the relationships between <i>antemortem</i> [¹¹ C]PIB-PET Centiloid values and <i>postmortem</i> measures of Alzheimer's disease neuropathology. <i>Alzheimer's and Dementia</i> , 2019, 15, 205-216.	0.8	155
56	Effects of estradiol and progesterone administration on human serotonin 2A receptor binding: a PET study. <i>Biological Psychiatry</i> , 2000, 48, 854-860.	1.3	152
57	Arterial Stiffness and β -Amyloid Progression in Nondemented Elderly Adults. <i>JAMA Neurology</i> , 2014, 71, 562.	9.0	152
58	Carbon 11-Labeled Pittsburgh Compound B and Carbon 11-Labeled (R)-PK11195 Positron Emission Tomographic Imaging in Alzheimer Disease. <i>Archives of Neurology</i> , 2009, 66, 60-7.	4.5	151
59	Serotonin alterations in anorexia and bulimia nervosa: New insights from imaging studies. <i>Physiology and Behavior</i> , 2005, 85, 73-81.	2.1	149
60	Visualization of fibrillar amyloid deposits in living, transgenic <i>Caenorhabditis elegans</i> animals using the sensitive amyloid dye, X-34. <i>Neurobiology of Aging</i> , 2001, 22, 217-226.	3.1	147
61	PET Imaging of Serotonin Type 2A Receptors in Late-Life Neuropsychiatric Disorders. <i>American Journal of Psychiatry</i> , 1999, 156, 1871-1878.	7.2	144
62	Exaggerated 5-HT1A but Normal 5-HT2A Receptor Activity in Individuals Ill with Anorexia Nervosa. <i>Biological Psychiatry</i> , 2007, 61, 1090-1099.	1.3	142
63	Imaging of CNS myelin by positron-emission tomography. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 9304-9309.	7.1	139
64	Amyloid- β ¹¹ C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. <i>Neurology</i> , 2015, 85, 692-700.	1.1	136
65	Amyloid Imaging With Carbon 11-Labeled Pittsburgh Compound B for Traumatic Brain Injury. <i>JAMA Neurology</i> , 2014, 71, 23.	9.0	132
66	Regional amyloid burden and intrinsic connectivity networks in cognitively normal elderly subjects. <i>Brain</i> , 2014, 137, 3327-3338.	7.6	130
67	Positron emission tomography imaging of amphetamine-induced dopamine release in the human cortex: A comparative evaluation of the high affinity dopamine D _{2/3} radiotracers [¹¹ C]FLB 457 and [¹¹ C]fallypride. <i>Synapse</i> , 2009, 63, 447-461.	1.2	127
68	3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. <i>Neurobiology of Aging</i> , 2010, 31, 1284-1303.	3.1	127
69	Reduced binding of [18F]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction. <i>Brain Research</i> , 1998, 813, 167-171.	2.2	121
70	Imaging Alzheimer Pathology in Late-Life Depression With PET and Pittsburgh Compound-B. <i>Alzheimer Disease and Associated Disorders</i> , 2008, 22, 261-268.	1.3	119
71	PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET. <i>Neurobiology of Aging</i> , 2009, 30, 1217-1226.	3.1	118
72	Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. <i>NeuroImage</i> , 2006, 33, 94-102.	4.2	116

#	ARTICLE	IF	CITATIONS
73	Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B. <i>Alzheimer's and Dementia</i> , 2012, 8, 496-501.	0.8	116
74	Impact of amyloid imaging on drug development in Alzheimer's disease. <i>Nuclear Medicine and Biology</i> , 2007, 34, 809-822.	0.6	115
75	Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson's disease. <i>Journal of Neurology</i> , 2007, 254, 84-90.	3.6	114
76	Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease. <i>JAMA Neurology</i> , 2014, 71, 1111.	9.0	112
77	Subjective Cognitive Complaints, Personality and Brain Amyloid-beta in Cognitively Normal Older Adults. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 985-993.	1.2	112
78	PET Measures of Amphetamine-Induced Dopamine Release in Ventral versus Dorsal Striatum. <i>Neuropsychopharmacology</i> , 1999, 21, 694-709.	5.4	110
79	Imaging Amyloid- β Deposits <i>In Vivo</i> . <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2002, 22, 1035-1041.	4.3	110
80	Consideration of Optimal Time Window for Pittsburgh Compound B PET Summed Uptake Measurements. <i>Journal of Nuclear Medicine</i> , 2009, 50, 348-355.	5.0	108
81	Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease. <i>Neuroscience Letters</i> , 2005, 380, 127-132.	2.1	104
82	Progression of Cerebral Amyloid Load Is Associated with the Apolipoprotein E ϵ 4 Genotype in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2010, 68, 879-884.	1.3	103
83	In Vivo Fibrillar β -Amyloid Detected Using [11C]PiB Positron Emission Tomography and Neuropathologic Assessment in Older Adults. <i>Archives of Neurology</i> , 2011, 68, 232-40.	4.5	102
84	Gender-specific aging effects on the serotonin 1A receptor. <i>Brain Research</i> , 2001, 895, 9-17.	2.2	99
85	Correspondence between in vivo 11C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques. <i>Acta Neuropathologica</i> , 2012, 124, 823-831.	7.7	98
86	Spatial patterns of brain amyloid- β burden and atrophy rate associations in mild cognitive impairment. <i>Brain</i> , 2011, 134, 1077-1088.	7.6	97
87	Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease. <i>NeuroImage</i> , 2007, 36, 298-312.	4.2	96
88	Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study. <i>Lancet Neurology</i> , 2015, 14, 804-813.	10.2	91
89	Small-molecule PET Tracers for Imaging Proteinopathies. <i>Seminars in Nuclear Medicine</i> , 2017, 47, 553-575.	4.6	91
90	Clinical severity of Alzheimer's disease is associated with PIB uptake in PET. <i>Neurobiology of Aging</i> , 2009, 30, 1902-1909.	3.1	89

#	ARTICLE	IF	CITATIONS
91	In vivo assessment of amyloid β deposition in nondemented very elderly subjects. <i>Annals of Neurology</i> , 2013, 73, 751-761.	5.3	89
92	The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation. <i>Current Opinion in Neurology</i> , 2008, 21, 683-687.	3.6	85
93	Serotonin transporter binding after recovery from eating disorders. <i>Psychopharmacology</i> , 2007, 195, 315-324.	3.1	83
94	Clinical Studies of Cerebral Blood Flow in Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 1997, 826, 254-262.	3.8	82
95	Amyloid- β Imaging in Older Adults Presenting to a Memory Clinic with Subjective Cognitive Decline: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S151-S159.	2.6	80
96	Advances in neuroimaging of traumatic brain injury and posttraumatic stress disorder. <i>Journal of Rehabilitation Research and Development</i> , 2009, 46, 717.	1.6	80
97	A Comparative Evaluation of the Dopamine D _{2/3} Agonist Radiotracer [¹¹ C]-N-Propyl-norapomorphine and Antagonist [¹¹ C]Raclopride to Measure Amphetamine-Induced Dopamine Release in the Human Striatum. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 333, 533-539.	2.5	78
98	Using Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta. <i>Advances in Pharmacology</i> , 2012, 64, 27-81.	2.0	78
99	Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study. <i>Acta Neuropathologica</i> , 2012, 123, 433-447.	7.7	78
100	Classification of amyloid-positivity in controls: Comparison of visual read and quantitative approaches. <i>NeuroImage</i> , 2013, 71, 207-215.	4.2	77
101	Cognitive trajectories associated with β -amyloid deposition in the oldest-old without dementia. <i>Neurology</i> , 2013, 80, 1378-1384.	1.1	77
102	Post-mortem histopathology underlying β -amyloid PET imaging following flutemetamol F 18 injection. <i>Acta Neuropathologica Communications</i> , 2016, 4, 130.	5.2	76
103	Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B. <i>Journal of Neuroscience Methods</i> , 2008, 172, 277-282.	2.5	75
104	Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. <i>Neuroimaging Clinics of North America</i> , 2003, 13, 781-789.	1.0	74
105	A comparison of the high-affinity peripheral benzodiazepine receptor ligands DAA1106 and (R)-PK11195 in rat models of neuroinflammation: implications for PET imaging of microglial activation. <i>Journal of Neurochemistry</i> , 2007, 102, 2118-2131.	3.9	72
106	Interaction between serotonin transporter and dopamine D2/D3 receptor radioligand measures is associated with harm avoidant symptoms in anorexia and bulimia nervosa. <i>Psychiatry Research - Neuroimaging</i> , 2013, 211, 160-168.	1.8	71
107	Incidental Cerebral Microbleeds and Cerebral Blood Flow in Elderly Individuals. <i>JAMA Neurology</i> , 2015, 72, 1021.	9.0	71
108	Tiagabine Increases [11C]flumazenil Binding in Cortical Brain Regions in Healthy Control Subjects. <i>Neuropsychopharmacology</i> , 2009, 34, 624-633.	5.4	70

#	ARTICLE	IF	CITATIONS
109	Development of a PET/SPECT Agent for Amyloid Imaging in Alzheimer's Disease. <i>Journal of Molecular Neuroscience</i> , 2004, 24, 055-062.	2.3	69
110	Imaging Technology for Neurodegenerative Diseases. <i>Archives of Neurology</i> , 2005, 62, 196.	4.5	69
111	Test-retest variability of serotonin 5-HT _{2A} receptor binding measured with positron emission tomography and [¹⁸ F]altanserin in the human brain. , 1998, 30, 380-392.		67
112	[¹⁸ F]AV-1451 positron emission tomography retention in choroid plexus: More than a "off-target" binding. <i>Annals of Neurology</i> , 2016, 80, 307-308.	5.3	66
113	Association of Brain Amyloid- β With Slow Gait in Elderly Individuals Without Dementia. <i>JAMA Neurology</i> , 2017, 74, 82.	9.0	66
114	The effects of normal aging on amyloid- β deposition in nondemented adults with Down syndrome as imaged by carbon 11-labeled Pittsburgh compound B. <i>Alzheimer's and Dementia</i> , 2016, 12, 380-390.	0.8	65
115	Markers of cholesterol transport are associated with amyloid deposition in the brain. <i>Neurobiology of Aging</i> , 2014, 35, 802-807.	3.1	62
116	Relative ¹¹ C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session ¹⁵ O-Water and ¹¹ C-PiB PET. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1199-1205.	5.0	62
117	Measurement of 5-HT _{1A} receptor binding in depressed adults before and after antidepressant drug treatment using positron emission tomography and [¹¹ C]WAY-100635. <i>Synapse</i> , 2007, 61, 523-530.	1.2	61
118	Longitudinal Cerebral Blood Flow and Amyloid Deposition: An Emerging Pattern?. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1465-1471.	5.0	59
119	Discussion of targeting proteins in vivo: in vitro guidelines. <i>Nuclear Medicine and Biology</i> , 2006, 33, 449-451.	0.6	58
120	Synthesis and evaluation of 2-(3-iodo-4-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in Alzheimer's disease. <i>Journal of Molecular Neuroscience</i> , 2002, 19, 11-16.	2.3	56
121	Effect of S-equol and Soy Isoflavones on Heart and Brain. <i>Current Cardiology Reviews</i> , 2019, 15, 114-135.	1.5	56
122	Positron emission tomography imaging of peripheral benzodiazepine receptor binding in human immunodeficiency virus-infected subjects with and without cognitive impairment. <i>Journal of NeuroVirology</i> , 2006, 12, 262-271.	2.1	55
123	β Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 209-219.	6.4	55
124	Analyses of [¹⁸ F]altanserin bolus injection PET data. II: Consideration of radiolabeled metabolites in humans. <i>Synapse</i> , 2001, 41, 11-21.	1.2	54
125	Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. <i>Brain</i> , 2006, 129, 2805-2807.	7.6	54
126	Grooved pegboard test as a biomarker of nigrostriatal denervation in Parkinson's disease. <i>Neuroscience Letters</i> , 2007, 424, 185-189.	2.1	53

#	ARTICLE	IF	CITATIONS
127	Positron emission tomography radioligands for <i>in vivo</i> imaging of A β plaques. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2013, 56, 89-95.	1.0	53
128	^{34}S Labeling of Abnormal Protein Aggregates During the Progression of Alzheimer's Disease. <i>Methods in Enzymology</i> , 2006, 412, 123-144.	1.0	52
129	The high affinity peripheral benzodiazepine receptor ligand DAA1106 binds specifically to microglia in a rat model of traumatic brain injury: Implications for PET imaging. <i>Experimental Neurology</i> , 2007, 207, 118-127.	4.1	51
130	Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer's disease from late-onset amyloid deposition. <i>Alzheimer's and Dementia</i> , 2018, 14, 743-750.	0.8	51
131	Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented Down syndrome population. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 9, 1-9.	2.4	49
132	Comparison of qualitative and quantitative imaging characteristics of [^{11}C]PiB and [^{18}F]flutemetamol in normal control and Alzheimer's subjects. <i>NeuroImage: Clinical</i> , 2015, 9, 592-598.	2.7	48
133	Effects of Lipophilicity on the Affinity and Nonspecific Binding of Iodinated Benzothiazole Derivatives. <i>Journal of Molecular Neuroscience</i> , 2003, 20, 255-260.	2.3	47
134	Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET. <i>NeuroImage</i> , 2011, 55, 933-941.	4.2	47
135	Amphetamine induced dopamine release increases anxiety in individuals recovered from anorexia nervosa. <i>International Journal of Eating Disorders</i> , 2012, 45, 263-271.	4.0	47
136	Amyloid pathway-based candidate gene analysis of [^{11}C]PiB-PET in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. <i>Brain Imaging and Behavior</i> , 2012, 6, 1-15.	2.1	47
137	Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging. <i>Molecular Psychiatry</i> , 2021, 26, 309-321.	7.9	47
138	Amyloid imaging in dementias with atypical presentation. , 2012, 8, 389-398.		46
139	Amyloid, neurodegeneration, and small vessel disease as predictors of dementia in the oldest-old. <i>Neurology</i> , 2014, 83, 1804-1811.	1.1	46
140	Longitudinal in Vivo Positron Emission Tomography Imaging of Infected and Activated Brain Macrophages in a Macaque Model of Human Immunodeficiency Virus Encephalitis Correlates with Central and Peripheral Markers of Encephalitis and Areas of Synaptic Degeneration. <i>American Journal of Pathology</i> , 2008, 172, 1603-1616.	3.8	44
141	In Vivo Evidence for Low Striatal Vesicular Monoamine Transporter 2 (VMAT2) Availability in Cocaine Abusers. <i>American Journal of Psychiatry</i> , 2012, 169, 55-63.	7.2	44
142	Association of plasma and cortical amyloid beta is modulated by APOE ϵ 4 status. <i>Alzheimer's and Dementia</i> , 2014, 10, e9-e18.	0.8	43
143	Synthesis and in vitro evaluation of 2,3-dimethoxy-5-(fluoroalkyl)-substituted benzamides: high-affinity ligands for CNS dopamine D2 receptors. <i>Journal of Medicinal Chemistry</i> , 1991, 34, 1612-1624.	6.4	41
144	[^{125}I]5-iodo-6-nitroquipazine: a potent and selective ligand for the 5-hydroxytryptamine uptake complex. II. In vivo studies in rats. <i>Brain Research</i> , 1993, 619, 236-246.	2.2	41

#	ARTICLE	IF	CITATIONS
145	Positron emission tomography imaging of dopamine D2/3 receptors in the human cortex with [¹¹ C]FLB 457: Reproducibility studies. <i>Synapse</i> , 2011, 65, 35-40.	1.2	41
146	[125I]5-iodo-6-nitroquipazine: a potent and selective ligand for the 5-hydroxytryptamine uptake complex. I. In vitro studies. <i>Brain Research</i> , 1993, 619, 229-235.	2.2	39
147	Regional cerebral blood flow after recovery from anorexia or bulimia nervosa. <i>International Journal of Eating Disorders</i> , 2007, 40, 488-492.	4.0	39
148	Lack of association between 11C-PiB and longitudinal brain atrophy in non-demented older individuals. <i>Neurobiology of Aging</i> , 2011, 32, 2123-2130.	3.1	39
149	Direct Comparison of the Tau PET Tracers [¹⁸ F]-Flortaucipir and [¹⁸ F]-MK-6240 in Human Subjects. <i>Journal of Nuclear Medicine</i> , 2022, 63, 108-116.	5.0	39
150	PET imaging of brain macrophages using the peripheral benzodiazepine receptor in a macaque model of neuroAIDS. <i>Journal of Clinical Investigation</i> , 2004, 113, 981-989.	8.2	39
151	Effects of soy isoflavones on cognitive function: a systematic review and meta-analysis of randomized controlled trials. <i>Nutrition Reviews</i> , 2020, 78, 134-144.	5.8	38
152	In vivo imaging of the 5-hydroxytryptamine reuptake site in primate brain using single photon emission computed tomography and [123I]5-iodo-6-nitroquipazine. <i>European Journal of Pharmacology</i> , 1993, 242, 189-193.	3.5	37
153	Synthesis and ¹²⁵ I-amyloid binding properties of rhenium 2-phenylbenzothiazoles. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 2258-2262.	2.2	37
154	Specific to nonspecific binding in radiopharmaceutical studies: it's not so simple as it seems!. <i>Nuclear Medicine and Biology</i> , 2009, 36, 235-237.	0.6	37
155	[11C]flumazenil Binding Is Increased in a Dose-Dependent Manner with Tiagabine-Induced Elevations in GABA Levels. <i>PLoS ONE</i> , 2012, 7, e32443.	2.5	37
156	MR atlas of the baboon brain for functional neuroimaging. <i>Brain Research Bulletin</i> , 2002, 58, 429-438.	3.0	36
157	Amyloid deposition and brain structure as long-term predictors of MCI, dementia, and mortality. <i>Neurology</i> , 2018, 90, e1920-e1928.	1.1	36
158	PET imaging of brain macrophages using the peripheral benzodiazepine receptor in a macaque model of neuroAIDS. <i>Journal of Clinical Investigation</i> , 2004, 113, 981-989.	8.2	36
159	Evaluation of dopamine D _{2/3} -specific binding in the cerebellum for the positron emission tomography radiotracer [¹¹ C]FLB 457: Implications for measuring cortical dopamine release. <i>Synapse</i> , 2011, 65, 991-997.	1.2	35
160	Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid- ¹²⁵ I plaques in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2020, 140, 463-476.	7.7	34
161	Analyses of [18F]altanserin bolus injection PET data. I: Consideration of radiolabeled metabolites in baboons. <i>Synapse</i> , 2001, 41, 1-10.	1.2	33
162	5-HT _{1A} receptor binding is increased after recovery from bulimia nervosa compared to control women and is associated with behavioral inhibition in both groups. <i>International Journal of Eating Disorders</i> , 2011, 44, 477-487.	4.0	33

#	ARTICLE	IF	CITATIONS
163	Amyloid β Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia. <i>JAMA Neurology</i> , 2018, 75, 88.	9.0	33
164	[125I]5-Iodo-6-nitro-2-piperazinylquinoline: a potent and selective ligand for the serotonin uptake complex. <i>European Journal of Pharmacology</i> , 1992, 210, 103-104.	3.5	32
165	Targeting Prion Amyloid Deposits In Vivo. <i>Journal of Neuropathology and Experimental Neurology</i> , 2004, 63, 775-784.	1.7	32
166	Cognitive aging in persons with minimal amyloid- β and white matter hyperintensities. <i>Neuropsychologia</i> , 2013, 51, 2202-2209.	1.6	31
167	Tenascin-C Is Associated with Cored Amyloid- β Plaques in Alzheimer Disease and Pathology Burdened Cognitively Normal Elderly. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 868-876.	1.7	31
168	Sleep moderates the relationship between amyloid beta and memory recall. <i>Neurobiology of Aging</i> , 2018, 71, 142-148.	3.1	31
169	Quantitative in vitro and ex vivo autoradiography of the β -adrenoceptor antagonist [3H]atopamezole. <i>European Journal of Pharmacology</i> , 1992, 224, 27-38.	3.5	29
170	Radiosynthesis, <i>In Vitro</i> and <i>In Vivo</i> Evaluation of [¹⁸ F]CBD-2115 as a First-in-Class Radiotracer for Imaging 4R-Tauopathies. <i>ACS Chemical Neuroscience</i> , 2021, 12, 596-602.	3.5	29
171	Imaging of dopamine $D_{2/3}$ agonist binding in cocaine dependence: A [¹¹ C]NPA positron emission tomography study. <i>Synapse</i> , 2011, 65, 1344-1349.	1.2	28
172	Evidence of increased serotonin-1A receptor binding in type 2 diabetes: a positron emission tomography study. <i>Brain Research</i> , 2002, 927, 97-103.	2.2	27
173	Characterization of bromine-76-labelled 5-bromo-6-nitroquipazine for PET studies of the serotonin transporter. <i>Nuclear Medicine and Biology</i> , 1999, 26, 501-507.	0.6	26
174	Evaluation of [3H]paroxetine as an in vivo ligand for serotonin uptake sites: A quantitative autoradiographic study in the rat brain. <i>Synapse</i> , 1993, 13, 1-9.	1.2	24
175	Positron emission tomography imaging of $D_{2/3}$ agonist binding in healthy human subjects with the radiotracer [¹¹ C]-N-propyl- α -norapomorphine: Preliminary evaluation and reproducibility studies. <i>Synapse</i> , 2009, 63, 574-584.	1.2	24
176	Amphetamine-Induced Striatal Dopamine Release Measured With an Agonist Radiotracer in Schizophrenia. <i>Biological Psychiatry</i> , 2018, 83, 707-714.	1.3	24
177	Alzheimer-Like Pattern of Hypometabolism Emerges with Elevated Amyloid- β Burden in Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 631-644.	2.6	23
178	Sequential H(2)(15)O PET studies in baboons: before and after amphetamine. <i>Journal of Nuclear Medicine</i> , 2002, 43, 1090-100.	5.0	23
179	Synthesis and ¹¹ C-labelling of (E,E)-1-(3,4-dihydroxystyryl)-4-(3-methoxy-4-hydroxystyryl) benzene for PET imaging of amyloid deposits?. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2002, 45, 647-664.	1.0	22
180	Preventive immunization of aged and juvenile non-human primates to beta-amyloid. <i>Journal of Neuroinflammation</i> , 2012, 9, 84.	7.2	22

#	ARTICLE	IF	CITATIONS
181	Development and Screening of Contrast Agents for In Vivo Imaging of Parkinson's Disease. <i>Molecular Imaging and Biology</i> , 2013, 15, 585-595.	2.6	21
182	Dopaminergic activity and altered reward modulation in anorexia nervosa—insight from multimodal imaging. <i>International Journal of Eating Disorders</i> , 2017, 50, 593-596.	4.0	21
183	What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies. <i>Journal of Nuclear Medicine</i> , 2021, 62, 614-619.	5.0	21
184	Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography. <i>Journal of Medicinal Chemistry</i> , 1984, 27, 1071-1077.	6.4	19
185	Synthesis of 2,3-dimethoxy-5-iodobenzoic acid. <i>Journal of Organic Chemistry</i> , 1991, 56, 5451-5456.	3.2	19
186	Amyloid accumulation in Down syndrome measured with amyloid load. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12020.	2.4	19
187	Binding Potency of Paroxetine Analogues for the 5-Hydroxytryptamine Uptake Complex*. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 44, 801-805.	2.4	18
188	Design, synthesis and structure–activity relationship of rhenium 2-arylbenzothiazoles as β -amyloid plaque binding agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 1720-1726.	2.2	18
189	Human Biodistribution and Dosimetry of the D2/3 Agonist 11C-N-Propylnorapomorphine (11C-NPA) Determined from PET. <i>Journal of Nuclear Medicine</i> , 2009, 50, 814-817.	5.0	17
190	Prefrontal and Striatal Dopamine Release Are Inversely Correlated in Schizophrenia. <i>Biological Psychiatry</i> , 2022, 92, 791-799.	1.3	17
191	Synthesis of ^{123}I -and labelled 5-iodo-6-nitroquipazine. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1994, 34, 905-913.	1.0	16
192	Advances in PET Imaging of Degenerative, Cerebrovascular, and Traumatic Causes of Dementia. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 57-87.	4.6	16
193	Amyloid-Beta Deposition is Associated with Increased Medial Temporal Lobe Activation during Memory Encoding in the Cognitively Normal Elderly. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 551-560.	1.2	16
194	Influence of apolipoprotein-E genotype on brain amyloid load and longitudinal trajectories. <i>Neurobiology of Aging</i> , 2020, 94, 111-120.	3.1	15
195	PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer's disease progression in Down syndrome. <i>NeuroImage</i> , 2021, 228, 117728.	4.2	15
196	No effect of dopamine depletion on the binding of the high-affinity D2/3 radiotracer [^{11}C]FLB 457 in the human cortex. <i>Synapse</i> , 2010, 64, 879-885.	1.2	14
197	[^{18}F]FDG, [^{11}C]PiB, and [^{18}F]AV-1451 PET Imaging of Neurodegeneration in Two Subjects With a History of Repetitive Trauma and Cognitive Decline. <i>Frontiers in Neurology</i> , 2019, 10, 831.	2.4	14
198	An efficient synthesis of the precursors of [^{11}C]MDL 100907 labeled in two specific positions. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1999, 42, 949-957.	1.0	13

#	ARTICLE	IF	CITATIONS
199	Distribution of 1-(2-Deoxy-2-fluoro- β -D-arabinofuranosyl) Uracil in Mice Bearing Colorectal Cancer Xenografts. <i>Clinical Cancer Research</i> , 2004, 10, 6669-6676.	7.0	13
200	Binding Potency of 6-Nitroquipazine Analogues for the 5-Hydroxytryptamine Reuptake Complex. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 46, 751-754.	2.4	13
201	Imaging Tau Deposits In Vivo: Progress in Viewing More of The Proteopathy Picture. <i>Neuron</i> , 2013, 79, 1035-1037.	8.1	13
202	Impact of partial volume correction on the regional correspondence between in vivo [C-11]PiB PET and postmortem measures of A β load. <i>NeuroImage: Clinical</i> , 2018, 19, 182-189.	2.7	13
203	Comparison of longitudinal A β in nondemented elderly and Down syndrome. <i>Neurobiology of Aging</i> , 2019, 73, 171-176.	3.1	13
204	Fluoroalkylbenzenes: Synthesis of (S)-2,3-Dimethoxy-5-[(3-fluoropropyl)-6-hydroxy-N-(1-ethyl-2-pyrrolidinyl)methyl]benzamide. <i>Journal of Fluorine Chemistry</i> , 1991, 51, 149-152.	1.7	12
205	P2-031 Amyloid deposits in transgenic PS1/APP mice do not bind the amyloid pet tracer, PIB, in the same manner as human brain amyloid. <i>Neurobiology of Aging</i> , 2004, 25, S232-S233.	3.1	12
206	Cerebral Amyloid Deposition and Dual-Tasking in Cognitively Normal, Mobility Unimpaired Older Adults. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016, 72, glw211.	3.6	12
207	Synthesis of 122I- and 125I-labelled meta-dimethoxy-N,N-dimethylidophenylisopropylamines. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1986, 23, 115-125.	1.0	11
208	Synthesis and in vivo evaluation of 122I- and 131I-labelled iodoperidol, a potential agent for the tomographic assessment of cerebral perfusion. <i>International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology</i> , 1987, 14, 91-98.	0.3	11
209	Quantification of 5-HT _{1A} and 5-HT _{2A} receptor Binding in Depressed Suicide Attempters and Non-Attempters. <i>Archives of Suicide Research</i> , 2019, 23, 122-133.	2.3	11
210	High pressure nucleophilic fluoride-ion substitution reactions: formation of fluoroalkylbenzenes. <i>Journal of Fluorine Chemistry</i> , 1996, 78, 121-129.	1.7	10
211	Positron emission tomography radiochemistry. <i>Neuroimaging Clinics of North America</i> , 2003, 13, 671-687.	1.0	10
212	Associations of β -producing status with white matter lesion and amyloid β deposition in cognitively normal elderly Japanese. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12089.	3.7	10
213	Relationship of amyloid β 1-42 in blood and brain amyloid: Ginkgo Evaluation of Memory Study. <i>Brain Communications</i> , 2020, 2, fcz038.	3.3	10
214	Synthesis of 1-[2,5-dimethoxy-4-(β -fluoroethyl)phenyl]-2-aminopropane: studies related to 18F-labeled serotonin receptor ligands. <i>Tetrahedron Letters</i> , 1988, 29, 6537-6539.	1.4	9
215	Whatever Happened to Pittsburgh Compound-A?. <i>Alzheimer Disease and Associated Disorders</i> , 2008, 22, 198-203.	1.3	9
216	Relationships Between Executive Control Circuit Activity, Amyloid Burden, and Education in Cognitively Healthy Older Adults. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, 1360-1371.	1.2	9

#	ARTICLE	IF	CITATIONS
217	Neurofibrillary tau depositions emerge with subthreshold cerebral beta-amyloidosis in down syndrome. <i>NeuroImage: Clinical</i> , 2021, 31, 102740.	2.7	9
218	Amyloid Imaging with PET in Alzheimer's Disease, Mild Cognitive Impairment, and Clinically Unimpaired Subjects. , 2009, , 119-147.		9
219	Stereoconservative synthesis of the enantiomerically pure precursors of [11C](+)-McN 5652 and [11C]($\hat{\wedge}$)-McN 5652. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1998, 41, 9-17.	1.0	8
220	Characterization of the Radiolabeled Metabolites of [18 F]Altanserin: Implications for Kinetic Modeling. , 1998, , 293-298.		8
221	Comparison of the binding of $3\hat{\wedge}^2$ -F-PiB and PiB in human brain homogenates. <i>NeuroImage</i> , 2008, 41, T113-T114.	4.2	8
222	Association Between Amyloid- $\hat{1}^2$, Small-vessel Disease, and Neurodegeneration Biomarker Positivity, and Progression to Mild Cognitive Impairment in Cognitively Normal Individuals. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 1753-1760.	3.6	8
223	11C -PiB PET can underestimate brain amyloid- $\hat{1}^2$ burden when cotton wool plaques are numerous. <i>Brain</i> , 2022, 145, 2161-2176.	7.6	8
224	Molecular targets. <i>Nuclear Medicine and Biology</i> , 2006, 33, 1.	0.6	7
225	Patterns of glucose hypometabolism in Down syndrome resemble sporadic Alzheimer's disease except for the putamen. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12138.	2.4	7
226	Beyond monoamines: I. Novel targets and radiotracers for Positron emission tomography imaging in psychiatric disorders. <i>Journal of Neurochemistry</i> , 2023, 164, 364-400.	3.9	7
227	An open-label positron emission tomography study to evaluate serotonin transporter occupancy following escalating dosing regimens of (\hat{R})- $\hat{\wedge}$ -desmethylvenlafaxine and racemic $\hat{\wedge}$ -desmethylvenlafaxine. <i>Synapse</i> , 2018, 72, e22021.	1.2	6
228	Amyloid deposition is associated with different patterns of hippocampal connectivity in men versus women. <i>Neurobiology of Aging</i> , 2019, 76, 141-150.	3.1	6
229	Development of a PET radioligand selective for cerebral amyloid angiopathy. <i>Nuclear Medicine and Biology</i> , 2021, 92, 85-96.	0.6	6
230	Human Biodistribution and Dosimetry of the PET Radioligand [11C]Flumazenil (FMZ). <i>Molecular Imaging and Biology</i> , 2012, 14, 115-122.	2.6	5
231	The Relationship of Current Cognitive Activity to Brain Amyloid Burden and Glucose Metabolism. <i>American Journal of Geriatric Psychiatry</i> , 2018, 26, 977-984.	1.2	5
232	An Effect of Education on Memory-Encoding Activation in Subjective Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 1065-1078.	2.6	5
233	First PET Study with a Benzothiazol Amyloidimaging Agent (PiB) in Alzheimer's Disease Patients and Healthy Volunteers. , 2004, , 123-137.		4
234	Positron Emission Tomography Agents for Central Nervous System Drug Development Applications. <i>Annual Reports in Medicinal Chemistry</i> , 2005, 40, 49-68.	0.9	4

#	ARTICLE	IF	CITATIONS
235	Synthesis and evaluation of high affinity, aryl-substituted [18F]fluoropropylbenzamides for dopamine D-2 receptor studies. <i>International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology</i> , 1992, 19, 571-588.	0.3	3
236	Serotonin transporter binding after recovery from eating disorders. <i>Psychopharmacology</i> , 2008, 197, 521-522.	3.1	3
237	Simplified quantification of PIB amyloid imaging PET studies. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S589-S589.	4.3	3
238	Radiopharmaceutical space. <i>Nuclear Medicine and Biology</i> , 2006, 33, 829.	0.6	2
239	Serotonin Transporter Binding In Vivo. , 2001, , 265-271.		2
240	Low untreated systolic blood pressure over 18 years is associated with survival free of dementia age 90+. <i>Alzheimer's and Dementia</i> , 2022, , .	0.8	2
241	Development of Benzothiazole Amyloid-Imaging Agents. , 2004, , 113-122.		1
242	Imaging Inflammation. , 2005, , 445-461.		1
243	Positron emission tomography imaging of amyloid-beta plaque deposition: a decade of translation. <i>Journal of Translational Medicine</i> , 2012, 10, .	4.4	1
244	Testâ€retest variability of serotonin 5â€HT2A receptor binding measured with positron emission tomography and [18F]altanserin in the human brain. <i>Synapse</i> , 1998, 30, 380-392.	1.2	1
245	Statistical Methods for Processing Neuroimaging Data from Two Different Sites with a Down Syndrome Population Application. <i>Communications in Computer and Information Science</i> , 2020, , 367-379.	0.5	1
246	Jointâ€label fusion brain atlases for dementia research in Down syndrome. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	2.4	1
247	In Vivo Imaging of Alzheimer Pathology in Transgenic Mice using Multiphoton Microscopy. <i>Research and Perspectives in Alzheimer's Disease</i> , 2004, , 33-45.	0.1	0
248	P2-063 In vivo dynamics of amyloid associated neuritic dystrophy before and after anti-AÎ² immunotherapy. <i>Neurobiology of Aging</i> , 2004, 25, S241-S242.	3.1	0
249	P2-156 Development of amyloid-imaging agents for both pet and spect. <i>Neurobiology of Aging</i> , 2004, 25, S270.	3.1	0
250	P2-186 In vivo imaging of prion amyloid deposits. <i>Neurobiology of Aging</i> , 2004, 25, S280-S281.	3.1	0
251	Evaluation of amyloid and tau PET quantitation methods using a 3Dâ€printed anatomically accurate brain phantom. <i>Alzheimer's and Dementia</i> , 2020, 16, e045455.	0.8	0
252	Comparing Pathological Risk Factors for Dementia between Cognitively Normal Japanese and Americans. <i>Brain Sciences</i> , 2021, 11, 1180.	2.3	0

#	ARTICLE	IF	CITATIONS
253	PET imaging of 5-HT1A receptors in late-life depression: Relationship to treatment response. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S323-S323.	4.3	0
254	The high-affinity peripheral benzodiazepine receptor ligand [11C]DAA1106 can be used to image microglia in animal models of Parkinson's disease and neuroinflammation in vivo using PET.. FASEB Journal, 2007, 21, A29.	0.5	0